Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03758443 · ClinicalTrials.gov registry record · Phase 2
Efficacy & Safety of TD-1473 in Ulcerative Colitis
A Phase 2 study, sponsored by Theravance Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
NCT03758443 is a Phase 2 study that was terminated before completion, run by Theravance Biopharma. The registered enrollment target is 239 participants.
The verdict
NCT03758443, a Phase 2 study, was terminated before completion, sponsored by Theravance Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
Study Summary
A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG TD-1473 Dose A
- DRUG TD-1473 Dose B
- DRUG TD-1473 Dose C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2021-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03758443
The ClinicalTrials.gov registry entry for NCT03758443 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03758443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03758443 about?
NCT03758443 is a clinical study titled "Efficacy & Safety of TD-1473 in Ulcerative Colitis". A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.
What is the current status of trial NCT03758443?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2019-03-11. Estimated completion is 2021-10-20.
What interventions are being tested in trial NCT03758443?
The interventions under investigation include: Placebo (DRUG), TD-1473 Dose A (DRUG), TD-1473 Dose B (DRUG), TD-1473 Dose C (DRUG).
Who is sponsoring clinical trial NCT03758443?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.